A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Study sponsor: Cytokinetics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-06-07Actual
Enrollment · participants71Actual
Source updated2024-08-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.